# US 2024/0402195 A1 · Methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0402195 A1
- Document ID: US20240402195A1
- Status: Published application
- Kind: A1
- Application number: 18/814,640
- Filed: 2024-08-26
- Published: 2024-12-05
- Earliest claimed: 2017-07-03
- Assignees: Abbott Laboratories
- Applicants: Abbott Laboratories
- Inventors: Gangamani S. Beligere; Melissa B. Brenna; Jessica Grieshaber; David Pacenti; Saul A. Datwyler; John M. Ramp
- Web page: https://patentgrep.com/patent/US20240402195A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2333/914: Hydrolases (3)
- G01N 2800/2814: Dementia; Cognitive disorders
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein are improved methods of processing, measuring, and detecting levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) in blood samples taken from a human subject at time points within about 8 hours (or about 8 hours or less) after obtaining the sample from the subject. UCH-L1 is an early biomarker for traumatic brain injury (TBI), and there is a need for improved methods for assessing UCH-L1 in blood can aid in the diagnosis and evaluation of a human subject who has sustained or may have sustained a head injury.

## Claims

### Claim 1

In an improvement of a method of measuring an amount of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) in a whole blood sample obtained from a subject, wherein said improvement comprises processing the sample within no more than about eight hours after the sample is obtained from the subject to avoid a rise in UCH-L1 level that results from storage of the sample.

### Claim 2 (depends on 1)

The improvement of claim 1, wherein the sample is processed within a period of time after the sample is obtained from the subject selected from the group consisting of: (a) from about zero hours to about 6 hours; (b) from about zero hours to about 4 hours; (c) from about zero hours to about 2 hours; and (d) from about zero hours to about 1 hour.

### Claim 3 (depends on 1)

The improvement of claim 1, wherein the sample is processed within a period of time after the sample is obtained from the subject selected from the group consisting of: (a) from about 1 hour to about 8 hours; (b) from about 1 hour to about 6 hours; (c) from about 1 hour to about 4 hours; and (d) from about 1 hour to about 2 hours.

### Claim 4 (depends on 1, 2, 3)

The improvement of any one of claims 1-3, wherein processing the sample comprises separating plasma from blood cells in the sample; and, subsequently performing a test using the plasma that measures the amount of UCH-L1.

### Claim 5 (depends on 1, 2, 3, 4)

The improvement of any one of claims 1-4, wherein the sample is obtained from the subject using a container comprising an anticoagulant selected from the group consisting of heparin and EDTA.

### Claim 6 (depends on 1, 2, 3, 4)

The improvement of any one of claims 1-4, wherein processing the sample comprises separating serum from any clots that arise in the sample; and, subsequently performing a test using the serum that measures the amount of UCH-L1.

### Claim 7 (depends on 6)

The improvement of claim 6, wherein the sample is collected using a serum collection tube.

### Claim 8 (depends on 1, 2, 3)

The improvement of any one of claims 1-3, wherein processing the sample comprises performing a test that measures the amount of UCH-L1 in the sample.

### Claim 9 (depends on 4, 5, 6, 7, 8)

The improvement of any one of claims 4-8, wherein the test comprises any method by which UCH-L1 amount can be assessed.

### Claim 10 (depends on 9)

The improvement of claim 9, wherein the test is selected from the group consisting of an immunoassay, chemical analysis, SDS PAGE and Western blot analysis, electrophoresis analysis, a protein assay, a competitive binding assay, a functional protein assay, chromatography, and spectrophotometry.

### Claim 11 (depends on 4, 5, 6, 7, 8, 9, 10)

The improvement of any one of claims 4-10, wherein the test is employed in a clinical chemistry format.

### Claim 12 (depends on 10, 11)

The improvement of claim 10 or 11, wherein the test is an immunoassay comprising:
a) contacting the sample, either simultaneously or sequentially, in any order with:
(1) at least one capture antibody, which binds to an epitope on UCH-L1 or UCH-L1 fragment to form a capture antibody-UCH-L1 antigen complex, and
(2) at least one detection antibody which includes a detectable label and binds to an epitope on UCH-L1 that is not bound by the capture antibody, to form a UCH-L1 antigen-detection antibody complex,
such that a capture antibody-UCH-L1 antigen-detection antibody complex is formed, and
b) measuring the amount or concentration of UCH-L1 in the sample based on the signal generated by the detectable label in the capture antibody-UCH-L1 antigen-detection antibody complex.

### Claim 13 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12)

The improvement of any one of claims 4-12, wherein the sample is maintained at room temperature for some period of time during the time point that the sample is obtained from the subject to a time point when the test is performed.

### Claim 14 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12)

The improvement of any one of claims 4-12, wherein the sample is maintained at a temperature from about 2° C. to about 8° C. for some period of time during the time point that the sample is obtained from the subject to the time point when the test is performed.

### Claim 15 (depends on 8, 9, 10, 11, 12)

The improvement of any one of claims 8-12, wherein the sample is not mixed during the period of time after the sample is obtained from the subject to the time point when the test is performed.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The improvement of any one of claims 1-15, wherein the UCH-L1 amount in the sample from the subject is assessed as a measure of traumatic brain injury, wherein the subject may have sustained an injury to the head.

### Claim 17

A method of avoiding or preventing an increase or rise in ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) levels between the period of time a whole blood sample is obtained from a subject and prior to performing an assay on the sample, the method comprising the step of: processing the sample within no more than about eight hours after the sample is obtained from the subject to avoid an increase or rise in UCH-L1 level that results from storage of the sample prior to performing the assay.

### Claim 18 (depends on 17)

The method of claim 17, wherein the method avoids or prevents an erroneously high level of UCH-L1 in the sample between the period of time the sample is obtained from the subject and prior to performing the assay.

### Claim 19 (depends on 17)

The method of claim 17, wherein the sample is processed within a period of time after the sample is obtained from the subject selected from the group consisting of: (a) from about zero hours to about 6 hours; (b) from about zero hours to about 4 hours; (c) from about zero hours to about 2 hours; and (d) from about zero hours to about 1 hour.

### Claim 20 (depends on 17)

The method of claim 17, wherein the sample is processed within a period of time after the sample is obtained from the subject selected from the group consisting of: (a) from about 1 hour to about 8 hours; (b) from about 1 hour to about 6 hours; (c) from about 1 hour to about 4 hours; and (d) from about 1 hour to about 2 hours.

### Claim 21 (depends on 17, 18, 19, 20)

The method of any one of claims 17-20, further comprising subsequently performing an assay to measure the amount of UCH-L1 in the sample.

### Claim 22 (depends on 17, 18, 19, 20)

The method of any one of claims 17-20, wherein processing the sample comprises separating plasma from blood cells in the sample; and, subsequently performing an assay using the plasma that measures the amount of UCH-L1 in the sample.

### Claim 23 (depends on 17, 18, 19, 20, 21, 22)

The method of any one of claims 17-22, wherein the sample is obtained from the subject using a container comprising an anticoagulant selected from the group consisting of heparin and EDTA.

### Claim 24 (depends on 17, 18, 19, 20, 21, 22)

The method of any one of claims 17-22, wherein processing the sample comprises separating serum from any clots that arise in the sample; and, subsequently performing an assay using the serum that measures the amount of UCH-L1 in the sample

### Claim 25 (depends on 24)

The method of claim 24, wherein the sample is collected using a serum collection tube.

### Claim 26 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 17-25, wherein the assay comprises any method by which UCH-L1 amount can be assessed.

### Claim 27 (depends on 26)

The method of claim 26, wherein the assay is selected from the group consisting of an immunoassay, chemical analysis, SDS PAGE and Western blot analysis, electrophoresis analysis, a protein assay, a competitive binding assay, a functional protein assay, chromatography, and spectrophotometry.

### Claim 28 (depends on 21, 22, 23, 24, 25, 26)

The method of any one of claims 21-26, wherein the assay is employed in a clinical chemistry format.

### Claim 29 (depends on 27)

The method of claim 27, wherein the assay is an immunoassay comprising:
a) contacting the sample, either simultaneously or sequentially, in any order with:
(1) at least one capture antibody, which binds to an epitope on UCH-L1 or UCH-L1 fragment to form a capture antibody-UCH-L1 antigen complex, and
(2) at least one detection antibody which includes a detectable label and binds to an epitope on UCH-L1 that is not bound by the capture antibody, to form a UCH-L1 antigen-detection antibody complex,
such that a capture antibody-UCH-L1 antigen-detection antibody complex is formed, and
b) measuring the amount or concentration of UCH-L1 in the sample based on the signal generated by the detectable label in the capture antibody-UCH-L1 antigen-detection antibody complex.

### Claim 30 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 21-29, wherein the sample is maintained at room temperature for some period of time between the time point that the sample is obtained from the subject and the time point when the assay is performed.

### Claim 31 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 21-29, wherein the sample is maintained at a temperature from about 2° C. to about 8° C. for some period of time between the time point that the sample is obtained from the subject and the time point when the assay is performed.

### Claim 32 (depends on 25, 26, 27, 28, 29)

The method of any one of claims 25-29, wherein the sample is not mixed between the period of time between the time point that the sample is obtained from the subject and the time point when the test is performed.

### Claim 33 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 17-32, wherein the UCH-L1 amount in the sample from the subject is assessed as a measure of traumatic brain injury, wherein the subject may have sustained an injury to the head.

### Claim 34

In an improvement of a method of measuring an amount of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) in a whole blood sample obtained from a subject, wherein said improvement comprises reducing errors in UCH-L1 measurements by controlling preanalytical processing conditions.

### Claim 35 (depends on 34)

The improvement of claim 34, wherein controlling preanalytical processing conditions comprise processing the sample within on more than about eight hours after the sample is obtained from the subject.
